Park Ha Biological Technology Co., Ltd. is classed by the SEC under Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (industry code 2840), based in Wuxi City, CN. In its latest annual figures on file, for the fiscal year ended 2025-10-31, it reported revenue of $3 million and a loss of $24 million (its filed statements).
Product businessSoap, Detergents, Cleang Preparations, Perfumes, CosmeticsWuxi City, CNfilings since 20238 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2840, Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.0 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.7 out of ten, present 4.2 out of ten, future 6.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 6.7 out of ten. No warning events in its filings since 2023. 67th percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.1 out of ten. +9.6% a year over 4 filed years; profitable in 3 of 4. 51st percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.9 out of ten. Share count grew 8.5% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases. 9th percentile among 13 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 4.7 out of ten. ROE -610%: lost 610¢ per shareholder dollar. Leverage 33%: owes 33¢ per asset dollar. 47th percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.2 out of ten. bottom 32% of 15 in its family; net margin -965%. 32nd percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.7 out of ten. CrossAssetData estimate 4.7/10, confidence 20 of 100 (family median). 50th percentile among 12 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 7.3 out of ten. top 27% of 15 in its family for room to expand. 73rd percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 8.6 out of ten. top 14% of 15 in its family for growth drivers. 86th percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 1.1 out of ten. bottom 11% of 14 in its family for expectations against reality. 11th percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-03-02 for the period ended 2025-10-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-11. Filings on record since 2023. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Franchise Fees 60%, Products Sales Nonfranchisees 21%, Product Sales Franchisees 19%. As tagged in its annual report (Form 20-F/A, filed 2026-05-15).
Who runs it
Zhang, Xiaoqiu (CEO); Zhu, Xiaoyan (CFO); Wang, Li (alya) (COO); Li, Xinyu (CTO); Shan, Yanan (director); Sheng, Qixiong (director); Yu, Xiaozhong (director). 7 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.